Diffuse liver disease afflicts an estimated 80 million people in the United States, alone. Non-alcoholic fatty liver disease (NAFLD), an early feature of diffuse liver disease, is fatty infiltration of hepatocytes (steatosis), which often leads to inflammation and fibrosis, and potentially cirrhosis. Noninvasive methods have been developed in recent years to quantify NAFLD using magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound (US). However, a study comparing the accuracy of these three techniques to an established standard of reference like MR spectroscopy (MRS) remains to be performed. The overall goal of our work is to perform a pilot study to compare non-invasive quantitative biomarkers for accurate detection and quantitative assessment of hepatic steatosis, using MRI, CT and US.
The PI of this project was: J. Harald Kramer, MD
This project was funded by: Radiology RD
The term of this project was: January 2013 to August 2013
The number of subjects scanned during this project was: 50